

## (12) Translation of European patent specification

## (11) NO/EP 3601239 B1

**NORWAY** 

(19) NO (51) Int Cl.

 C07D 401/14 (2006.01)
 C07D 471/10 (2006.01)
 C07D 491/20 (2006.01)

 A61K 31/497 (2006.01)
 C07D 471/20 (2006.01)
 C07D 495/10 (2006.01)

 A61P 35/00 (2006.01)
 C07D 491/107 (2006.01)
 C07D 513/10 (2006.01)

 C07D 405/14 (2006.01)
 C07D 491/113 (2006.01)
 C07F 9/6558 (2006.01)

## **Norwegian Industrial Property Office**

(45) Translation Published 2024.11.04

(80) Date of The European Patent Office Publication of

the Granted Patent 2024.07.31

(86) European Application Nr. 18770877.1

(86) European Filing Date 2018.03.23

(87) The European Application's

Publication Date 2020.02.05

(30) Priority 2017.03.23, WO, PCT/IB17/051690

(84) Designated Contracting

States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT;

LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR

Designated Extension

States:

BA; ME

Designated validation

states MA; MD; TN

(73) Proprietor Jacobio Pharmaceuticals Co., Ltd., Unit 2, Building 5, BYBP No.88 Kechuang Street

6th Business Development Area Daxing, Beijing 101111, Kina

(72) Inventor MA, Cunbo, Unit 2 Building 5 BYBP No.88 Kechuang Street 6th Business

Development Area Daxing, Beijing 101111, Kina

GAO, Panliang, Unit 2 Building 5 BYBP No.88 Kechuang Street 6th Business

Development Area Daxing, Beijing 101111, Kina

HU, Shaojing, Unit 2 Building 5 BYBP No.88 Kechuang Street 6th Business

Development Area Daxing, Beijing 101111, Kina

XU, Zilong, Unit 2 Building 5 BYBP No.88 Kechuang Street 6th Business

Development Area Daxing, Beijing 101111, Kina

HAN, Huifeng, Unit 2 Building 5 BYBP No.88 Kechuang Street 6th Business

Development Area Daxing, Beijing 101111, Kina

WU, Xinping, Unit 2 Building 5 BYBP No.88 Kechuang Street 6th Business

Development Area Daxing, Beijing 101111, Kina

KANG, Di, Unit 2 Building 5 BYBP No.88 Kechuang Street 6th Business

Development Area Daxing, Beijing 101111, Kina

(74) Agent or Attorney ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS

(56) References

Cited: WO-A1-2007/057775, WO-A1-2015/107494, WO-A1-2018/013597, WO-A1-2016/203406,

WO-A1-2017/211303, WO-A1-2015/107495

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<a href="http://worldwide.espacenet.com">http://worldwide.espacenet.com</a>) or via the search engine on our website here: <a href="https://search.patentstyret.no/">https://search.patentstyret.no/</a>

## Patentkrav

1. Forbindelse som er

$$\begin{array}{c|c} CI & S - N & N \\ \hline \\ H_2N & M_2N & M_2N \end{array}$$

eller et farmasøytisk akseptabelt salt derav.

5

2. Forbindelsen ifølge krav 1, som er

$$H_2N$$